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Abstract
Background: Coronary artery disease (CAD) is a leading cause of morbidity and mortality worldwide. Many genetic
and environmental risk factors including atherogenic dyslipidemia contribute towards the development of CAD.
Functionally relevant mutations in the dyslipidemia-related genes and enzymes involved in the reverse cholesterol
transport system are associated with CAD and contribute to increased susceptibility of myocardial infarction (MI).
Method: Blood samples from 990 angiographically confirmed Saudi CAD patients with at least one event of
myocardial infarction were collected between 2012 and 2014. A total of 618 Saudi controls with no history or family
history of CAD participated in the study. Four polymorphisms, rs2230806, rs2066715 (ABCA1), rs5882, and rs708272
(CETP), were genotyped using TaqMan Assay.
Results: CETP rs5882 (OR = 1.45, P < 0.005) and ABCA1 rs2230806 (OR = 1.42, P = 0.017) polymorphisms were associated
with increased risk of CAD. However, rs708272 polymorphism showed protective effect (B1 vs. B2: OR = 0.80, P = 0.003
and B2B2 vs. B1B1: OR = 0.68, P = 0.012) while the ABCA1 variant rs2066715 was not associated.
Conclusion: This study is the first to report the association of these polymorphisms with CAD in the population
of the Eastern Province of Saudi Arabia. The rs5882 polymorphism (CETP) showed a significant association and
therefore could be a promising marker for CAD risk estimation while the rs708272 polymorphism had a protective
effect from CAD.
Keywords: Gene polymorphism, CAD, CETP, ABCA1, TaqMan Assay
Background
Coronary artery disease (CAD) is one of the leading
causes of morbidity and disability and the most common
cause of mortality worldwide equally among men and
women. CAD is a disease burden in both high- and low-
income countries [1, 2]. A study conducted on 17,232
people from Saudi Arabia revealed that 5.5 % had been
diagnosed with CAD, with a higher prevalence in urban
populations (6.2 %) compared to rural populations (4 %)
[3]. Platelet aggregation and thrombus formation follow-
ing the rupture of coronary atherosclerotic plaque is the
major cause of myocardial infarction (MI) [4–6].
Many extrinsic and intrinsic risk factors, including
hypertension, dyslipidemia, obesity, smoking, age, lack of
exercise, and diabetes, are established risk factors for MI
[7]. Atherogenic dyslipidemia is characterized by abnor-
mal levels of triglycerides, low- and high-density lipopro-
tein (LDL-C and HDL-C) [8–10]. Functionally relevant
mutations in the dyslipidemia-related genes and gene
encoding enzymes involved in the reverse cholesterol
transport system have been reported to be associated
with high-density lipoprotein-cholesterol (HDL-C) levels
[11–13]. Epidemiological and clinical studies have dem-
onstrated a contradictory association between HDL-C
concentrations and cardiovascular risk [10, 14, 15]. The
anti-atherogenic effect of HDL-C may act through sev-
eral mechanisms, such as anti-oxidation of low-density
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lipoprotein-cholesterol (LDL-C) and anti-inflammation
and inhibition of vascular endothelial cell apoptosis.
The reverse cholesterol transport system plays a vital
role in these processes [16], as it is involved in the trans-
portation of cholesterol from the peripheral tissues to the
liver, where cholesterol is secreted into bile. ATP-binding-
cassette A1 (ABCA1), apolipoprotein A-1 (ApoA-1), and
cholesteryl ester transfer protein (CETP) play important
roles in the reverse cholesterol transport system [17]. Cer-
tain ABCA1 polymorphisms have been reported to be as-
sociated with HDL-C concentrations, which in turn
indicate increased cardiovascular risk [18]. The potential
atherogenicity of CETP relates to its ability to transfer
cholesteryl esters from the anti-atherogenic HDLs to the
pro-atherogenic VLDL and LDL proteins. Mutations in
the CETP gene give rise to less functional protein, which
reduces the transfer of cholesteryl esters, and conse-
quently HDL levels are elevated [19]. ABCA1 and CETP,
variants including rs2230806, rs2066715, and rs5882, have
been associated with increased HDL-C concentrations
and rs708272 with a decreased risk for CAD [20, 21].
The objective of the present study is to evaluate the as-
sociation of the two ABCA1 polymorphisms, rs2230806
[R219K: c.656G>A (p.Arg219Lys)] and rs2066715 [V825I:
c.2473G>A (p.Val825Ile)], and two CETP polymorphisms,
rs5882 [V422I: c.1264G>A (p.Val422Ile)] and rs708272
[TaqIB: c.118+279G>A], with the risk of CAD in the
population of the Eastern Province of Saudi Arabia.
Results
Demographical and clinical data of cases and the control
group, including age, sex, clinical manifestations, and
biochemical parameters, are shown in Table 1. Patients
were classified into subgroups based on their hyperten-
sion and diabetes status. Hypertension and diabetes were
more prevalent in the patient group compared to the
control group.
All genotype frequencies of the control group were con-
sistent with Hardy-Weinberg equilibrium. The distribution
of analyzed genotype polymorphisms are shown in
Table 2. Since all the four SNPs had a G>A transition
substitution, the genotypes are denoted with the amino
acid change, except for Taq1B alleles, which are desig-
nated by B1 and B2. The genotype analysis showed
overall heterozygous polymorphism predominance in
rs2230806 of ABCA1, rs5882, and rs708272 of CETP
(Table 2).
The CETP rs708272 polymorphism showed a signifi-
cantly lower risk for CAD (B1B2+B2B2 vs. B1B1: OR =
0.68, 95 % CI 0.55–0.85, P = 0.0006 and B2B2 vs. B1B1:
OR = 0.68, 95 % CI 0.50–0.92, P = 0.012). There was also a
significant variation of B1B2 genotypes among patients
and controls (OR = 0.68, 95 % CI 0.54–0.86, P = 0.001).
Genotyping for the rs5882 polymorphism in CETP exon-
14 showed that the frequency of VI genotype was higher
in cases than in controls (52.8 vs. 48.0 %). Our analysis re-
vealed that CETP rs5882 polymorphism is associated with
an increased risk of CAD in our Saudi population study
dataset (VI+II vs. VV: OR = 1.42, 95 % CI 1.11–1.82,
P = 0.005; II vs. VV: OR = 1.37, 95 % CI 1.02–1.82, P =
0.031). Allele frequency analysis of the B2 allele of rs708272
of CETP (OR = 0.80, 95 % CI 0.69–0.92, P = 0.003) and the
K allele of rs2230806 of ABCA1 (OR = 1.17, 95 % CI 1.01–
1.35, P = 0.029) showed a significant difference between the
two tested groups (Table 2). The mutant KK genotype of
rs2230806 of ABCA1 is found to be associated with an in-
creased risk of CAD (RR vs. KK: OR = 1.42, 95 % CI 1.06–
1.91, P = 0.017). There were no significant differences in al-
lele and genotype frequencies of rs2066715 polymorphisms
in ABCA1 between the patient and control groups. The
power of the study observed was 100 % for protective effect
at odds ratio of 0.5 and 94.9 % at 0.7 for TaqIB, and for the
other three SNPs (R219K, V825I, and I405V), the results
ranged from 45.48 to 96.9 % for an odds ratio of 1.2–1.5.
A joint analysis of two SNPs of both ABCA1 and
CETP is shown in Table 3. All the combinations of the
CETP variants exhibited no association, except B1B1+VI
(OR = 1.7, 95 % CI 1.0–2.9, P = 0.048). On the other
hand, for ABCA1, RK+VV and RK+VI lacked an associ-
ation (Table 3). A sex-based analysis revealed a higher
frequency of B1B1 genotype in men and women with
CAD compared to their respective controls (Table 4).
There was no statistical significance in the distribution
of ABCA1 genotypes in the female cohort whereas in
the male cohort genotypes KK (OR = 1.8, P = 0.001) of
rs2230806 and VI (OR = 2.17, P = 0.041) of rs2066715
showed a significantly higher risk for CAD. In the CETP,
rs5882 polymorphisms II (OR = 1.98, 95 % CI 1.38–2.85,
P = 0.0002) revealed a significantly higher risk for CAD
in the male cohort. In the male and female cohorts,
rs708272 B1B2 and B2B2 genotypes showed a protective
effect for CAD, respectively. The rs2230806 and
rs2066715 of ABCA1 did not show any significant
Table 1 Demographic and clinical characteristics of study
subjects
Baseline characteristics Cases (N = 990) Controls (N = 618) P value
Age (years) 58.37 ± 12.91 54.8 ± 8.5 <0.0001a
Sex M:F 708:282 423:195 0.19b
Total cholesterol (mg/dl) 170.84 ± 48.39 171.58 ± 43.25 0.50a
LDL cholesterol (mg/dl) 103.82 ± 40.58 107.25 ± 35.35 0.005a
HDL cholesterol (mg/dl) 36.19 ± 9.88 50.22 ± 23.89 <0.0001a
Clinical Characteristics
Hypertension, n (%) 688 (69.5) 74 (12.0) <0.05b
Diabetes, n (%) 577 (58.3) 87(14.1) <0.05b
aStudent’s t test
bChi-square test
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Table 2 Association between ABCA1 and CETP genotypes and alleles with CAD
SNP Genotype/alleles Cases (N = 990) Control (N = 618) OR (95 % CI) P value
rs2230806 (R219K) RR 291 195 Ref
RK 473 317 0.9 (0.79–1.25) 0.999
KK 226 106 1.42 (1.06–1.91) 0.017
RK+KK 699 423 1.10 (0.89–1.37) 0.359
R(G) 1055 707 Ref
K(A) 925 529 1.17 (1.01–1.35) 0.029
rs2066715 (V825I) VV 945 597 Ref
VI 45 21 1.35 (0.79–2.29) 0.26
II 0 0 – –
VI+II 45 21 1.35 (0.79–2.29) 0.26
V(G) 1935 1215 Ref
I(A) 45 21 1.34 (0.79–2.26) 0.27
rs5882 (V422I) VV 178 147 Ref
VI 523 297 1.45 (1.12–1.88) 0.005
II 289 174 1.37 (1.02–1.82) 0.031
VI+II 812 471 1.42 (1.11–1.82) 0.005
V(G) 879 591 Ref
I(A) 1101 645 1.14 (0.99–1.32) 0.058
rs708272 (TaqIB) B1B1 376 183 Ref
B1B2 454 321 0.68 (0.54–0.86) 0.001
B2B2 160 114 0.68 (0.50–0.92) 0.012
B1B2+B2B2 614 435 0.68 (0.55–0.85) 0.0006
B1(G) 1206 687 Ref
B2(A) 774 549 0.80 (0.69–0.92) 0.003
Table 3 Association between joint analysis of two SNPs of ABCA1 gene and CETP gene with CAD
Gene Genotype Cases (N = 990) Controls (N = 618 ) OR 95 % CI P value
ABCA1 RR+VV 256 186 Ref
RR+VI 35 9 2.82 1.32–6.02 0.007
RK+VV 463 305 1.10 0.86–1.39 0.419
RK+VI 10 12 0.60 0.25–1.43 0.252
KK+VV 226 106 1.54 1.14–2.08 0.004
CETP B1B1+VV 46 31 Ref
B1B1+VI 180 71 1.70 1.0–2.90 0.048
B1B1+II 150 81 1.24 0.73–2.11 0.41
B1B2+VV 77 71 0.73 0.41–1.27 0.27
B1B2+VI 269 175 1.03 0.63––1.69 0.888
B1B2+II 108 75 0.97 0.56–1.66 0.913
B2B2+VV 55 45 0.82 0.45–1.50 0.527
B2B2+VI 74 51 0.97 0.54–1.74 0.939
B2B2+II 31 18 1.16 0.55–2.42 0.692
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association with an increased risk for CAD in the female
cohort compared to the control subjects.
Discussion
CAD is a multifactorial disease mediated through a com-
plex association of environmental and genetic factors
with ethnicity demonstrated to be an important deter-
minant of disease variability. The strength of the current
study is the selection of CAD patients from similar eth-
nic backgrounds. In the present study, two common
genetic variations in each ABCA1 and CETP gene were
studied with reference to their effect on CAD. We tested
four SNPs, namely rs2230806 (R219K), rs2066715
(V825I), rs5882 (V422I), and rs708272 (TaqIB) for their
association with CAD. CETP, located on chromosome
16q21, plays a crucial role in lipid metabolism, and nu-
merous SNPs in this gene have been reported to alter
the plasma HDL-C levels and function of CETP [22, 23].
Among the CETP SNPs, rs708272 is the one that is most
studied. Therefore, we investigated the association of
two SNPs of this gene and their risk for CAD in the
Saudi population.
Our overall results showed that the heterozygous and
mutant of rs708272 polymorphism may confer protection
against CAD (B1B2: OR = 0.68, P = 0.001; B2B2: OR =
0.68, P = 0.012) while those of rs5882 increased the risk of
CAD (VI: OR = 1.45, P = 0.005; II: OR = 1.37, P = 0.031).
Earlier studies had suggested that the CETP variant
rs5882 causes low CETP and is associated with higher
HDL and possibly with increased CAD among hyper-
triglyceridemia men [24, 25]. In contrast, in many recent
studies, the rs5882 polymorphism lacked any association
with CAD [26–29]. ABCA1 encodes an important protein
that facilitates the formation of HDL-C and regulates the
efflux of lipids from peripheral cells into lipid-poor ApoA1
particles, stimulating reverse cholesterol transport. [30]
The association between the ABCA1 gene polymorphisms
and CAD has been the focus for many studies [31–33].
The rs2230806 is the most common polymorphism of
ABCA1; the possible role of rs2230806 in cardiovascular
diseases is still debatable as numerous studies have re-
ported divergent results [34, 35]. The results of our study
revealed that the K variant of rs2230806 (P = 0.029) is as-
sociated with CAD, which is in line with Zargar et al. [36].
The rs2066715 of ABCA1 is not associated with an in-
creased risk of CAD. The frequency of the rare allele of
rs2066715 (0.02) showed a unique distribution compared
to the 1000 genome database (0.113) and Han Chinese
(0.44) population [37]. The K allele frequency of
rs2230806 (R219K) polymorphism in our study was 0.47
compared to 0.28–0.73 in earlier studies [18, 38, 39]. The
K allele frequency reported in our study is in line with
other reports, namely a European ancestry study which re-
ported a K allele frequency of 0.26–0.46 and a study on
Dutch men with proven CAD, which reported a frequency
of 0.46 [40, 41].
An analysis of the effect of a combination of ABCA1
genotypes on CAD showed that the RR+VI genotype
was significantly associated with a high risk of CAD
(OR = 2.82, 95 % CI 1.32–6.02, P = 0.007). However, an
analysis of the effect of the combination of CETP geno-
types on CAD showed no significant pattern. All other
combinations lacked a significant association with an OR
ranging from 0.73 to 1.24, except for B1B1+VI (OR = 1.7,
P = 0.048). The prevalence of CAD was higher in males
(M:F 708:282) than in females in the present study.
Homozygous mutant and heterozygous of rs5882 in men
and women were strongly associated with an increased
risk of CAD, while the other two ABCA1 polymorphisms
showed no significant association with CAD (OR = 0.73–
1.13) in the female cohort. Also, heterozygousity of
rs708272 alleles was strongly associated with an increased
risk of CAD (OR = 0.65, P = 0.002), a homozygous carriage
of rs5882, the rarer variants II causing amino acid
Table 4 Association between ABCA1 and CETP genotypes and CAD in male and female cohorts
Genotype Male cohort Female cohort
Cases (n = 708) Control (n = 423) OR (95 % CI) P value Cases (n = 282) Control (n = 195) OR (95 % CI) P value
R219K RR 212 137 Ref 79 58 Ref
RK 337 229 0.95 (0.72–1.24) 0.718 136 88 1.13 (0.73–1.74) 0.566
KK 159 57 1.80 (1.24–2.61) 0.001 67 49 1.0 (0.60–1.65) 0.987
V825I VV 676 414 Ref 269 183 Ref
VI 32 9 2.17 (1.02–4.60) 0.041 13 12 0.73 (0.32–1.65) 0.458
V422I VV 123 103 Ref 55 44 Ref
VI 376 232 1.35 (0.99–1.84) 0.052 147 65 1.80 (1.10–2.96) 0.018
II 209 88 1.98 (1.38–2.85) 0.0002 80 86 0.74 (0.45–1.22) 0.246
TaqIB B1B1 261 124 Ref 115 59 Ref
B1B2 340 247 0.65 (0.49–0.85) 0.002 114 74 0.79 (0.51–1.21) 0.282
B2B2 107 52 0.97 (0.65–1.45) 0.91 53 62 0.43 (0.27–0.71) 0.0008
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substitutions showed a strong association with an in-
creased risk of CAD (OR = 1.98, P = 0.0002) among the
male cohort. The CETP rs5882 polymorphism was found
to be associated with an increased risk for CAD in the
overall study population and also in the male and female
cohorts, which is in contrast to a recent study which re-
ported that this polymorphism is associated with a de-
creased risk of CAD and MI [42].
Studies conducted in other populations have correlated
the genotypes of ABCA1 and CETP and risk of CHD with
respect to its effect on HDL-C. A study of 119 patients in
Korea showed that the B1B1 genotype of the CETP Taq1B
polymorphism was associated with low HDL-C levels in
females and non-smoking males and may be an independ-
ent genetic risk factor for CAD [43]. In the present study,
the B2 allele of the CETP rs708272 polymorphism was as-
sociated with a reduced risk of CAD mediated by elevated
HDL-C concentrations. However, Borggreve et al. in their
prospective population-based study (PREVENT study) on
8141 Caucasians demonstrated that the B2 and I alleles of
the rs708272 (TaqIB) and rs5882 (V422I) of the CETP
gene were not associated with a decreased risk for CAD,
despite their HDL-C-raising effect suggesting that the risk
may be independent of the gene’s influence on HDL-C
levels [44]. Thus, the association of polymorphic CETP ge-
notypes with a decreased cardiovascular risk seems to be
independent of their effect on HDL-C levels [45–47].
Conclusion
This study is the first to report the association of these
polymorphisms with the development of CAD in a Saudi
population. A significant association of CETP rs5882
and ABCA1 rs2230806 polymorphism with CAD was
observed marking these polymorphisms as risk factors.
The rs708272 showed a protective effect for CAD, and
rs2066715 of ABCA1 gene lacked any association with
CAD, whereas the joint effect of the ABCA1 gene (RR
+VI and KK+VV) conferred a higher risk for CAD. A
sex difference subsists with a higher prevalence of CAD
among males (M:F 708:282). Female heterozygous and
male homozygous for the rs5882 were shown to have an
increased risk of CAD.
Methods
Study population
Patients reporting to the cardiac clinic at King Fahd
Hospital of the University, Al-Khobar, and other major
hospitals in the Eastern Province of Saudi Arabia were
screened, and angiographically confirmed CAD cases
with at least one event of MI (N = 990) were enrolled in
this study. A total of 618 age-matched normal Saudi
controls with no history or family history of CAD were
recruited from the blood banks of the same hospitals.
This study was approved by the Ethical Committee of
the University of Dammam. Signed written informed
consent was obtained from all participants.
Genotyping
Blood samples (5 ml) were obtained from 1608 subjects
in EDTA-coated tubes and DNA was extracted using
QIAamp DNA isolation kit (Qiagen, Germany) as per
the manufacturer’s instructions. Allele-Specific TaqMan®
PCR procedures were used to detect the genetic variants
rs2230806, rs2066715, rs708272, and rs5882.
Statistical analysis
The difference between cases and controls was evaluated
using t test for continuous variables and Chi-square test
for discrete variables. Allele frequencies were estimated
by direct counting of the test allele divided by the total
number of alleles. To assess the risk for CAD, odds ratio
was determined by univariate analysis. All statistical ana-
lyses were performed using SPSS software (version19).
The power of the study was calculated using online soft-
ware sampsize.sourceforge.net.
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